You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
阿斯利康與RQ生物達成協議以獲得新冠抗體療法的獨家授權
格隆匯5月17日丨阿斯利康(AZN.US)週二表示,該公司將支付高達1.57億美元的版權費,以獲得開發和銷售RQ Bio開發的一套臨牀前新冠抗體療法的獨家授權。實驗性抗體療法包括針對免疫系統受損人羣的療法,比如阿斯利康自己的抗體雞尾酒Evusheld,已經在多個國家獲得批准。阿斯利康最近表示有興趣增加其以免疫為重點的治療藥物的名單,此前在其季度報吿中設立了一個新的報吿部門,名為“疫苗和免疫療法”,包括其新冠產品。另外,公司正在對Evusheld進行融資,以部分彌補其新冠疫苗銷售的迅速萎縮。該疫苗去年是第二暢銷疫苗,但與輝瑞和Moderna的競爭對手競爭,並因生產受挫等因素陷入困境。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account